Pfizer
Public Statements Risk
The company is a high profile key player in big pharma but is insulated from customer'visibility by the structure of the US healthcare markets and the fact that people tend to know what drugs they use but not who manufactures them. The Pfizer website includes both DEI and Sustainability subsections, and has had a much higher profile and press relevance since COVID.

Political Contributions Risk
Goods Unite Us data shows that Pfizer is the second highest political contributor in the medical sector, but the size of donations are pretty evenly split between parties. It seems common for others in the sector to slightly favor the Republicans. It has been reported that Pfizer recently donated $1 million to the Republican Party of Kentucky to expand their headquarters.

Political Dichotomy Risk
Pfizer makes just under half its revenue in the US, with most revenue coming from 4 drugs: Paxlovid, Comirnaty, Eliquis, Prevnar Family; 2 COVID vaccines, a blood thinner, and a childhood pneumonia vaccine respectively. Selling, informational, and admin expenses are almost as big a share of revenue as Cost of Goods Sold. This could make them fairly vulnerable to boycotting. Additionally, Goodwill (branding/reputation with customers) is listed as 27% of Pfizer's Current Assets, possibly a reflection of how marketing-dependent their slice of Pharma is. This drastically increases their risk of a boycott but is neutralized somewhat by how middle of the road their donations are and how complex and consumer-independent much of the drug market is.

Associational Risk
Pfizer has heavily funded the controversial Dr. Mehmet Oz, who has been accused of spreading medical misinformation. Pfizer has also funded legislators who supported the Jan. 6 attack on the US Capital and legislators who are anti-LGBTQ+.

Brand Visibility Risk
Research revealed that Pfizer is heavily searched on Google; however, there are relatively few articles about the company itself.
